[
    {
        "title": "**C3 Purification:**",
        "body": "Step 1: Isolate Complement factor C3 by PEG precipitation from EDTA-treated human blood plasma and purify by DEAE and blue sepharose affinity chromatography \\(Smith, S.A., _et al._, Biochim Biophys Acta,"
    },
    {
        "title": "**1650**",
        "body": ", 30-39, 2003)."
    },
    {
        "title": "**C3b preparation:**",
        "body": "Step 2: Prepare purified C3b by performing limited trypsin digestion of C3 with sequencing grade trypsin \\(Roche). Perform the cleavage in the presence of N-Acetlyl-L-Threonine \\(AcT) to provide a nucleophile for covalent attachment of the side chain carbonyl of Gln991.  Activate the internal thioester \\(Law, A.S.K. & Dodds, A.W. Protein Science,"
    },
    {
        "title": "**6**",
        "body": ", 263-274, 1997) with 5% trypsin \\(w/w) for 2 min at 37°C, before adding 5% \\(w/w) soybean trypsin inhibitor \\(SBTI) \\(Sigma) to stop the reaction.\r\n\n\n \r\n\n\nStep 3: Remove trypsin and SBTI by perfusion chromatography using a BioCAD 20HQ column. \r\n\n\n \r\n\n\nStep 4: Visualize C3 and C3b by SDS-PAGE \\(4–12% gel) with Coomassie blue staining.  \r\n\n\n \r\n\n\nStep 5: Confirm esterification via mass spectroscopic analysis on tryptic digests of modified C3b. \r\n\n\n \r\n\n\nStep 6: Store modified protein at a concentration of 7.7 mg/ml in 20mM TRIS, pH 7.5 and a protein inhibitor cocktail \\(1M KH2PO4, 0.2 M EDTA, 0.2 M Benzamidine-HCl and 1mM PmSF)."
    },
    {
        "title": "**Crystallization:**",
        "body": "Step 7: Obtain crystals through vapor diffusion from 2 μl of the protein solution mixed with an equal volume of well solution.  Wells should contain 200 mM TRIS, pH 7.5, 100 mM NaCl, 20 mM LiCl and 15% PEG6000."
    }
]